搜索结果: 1-15 共查到“医学 non-small cell lung cancer”相关记录15条 . 查询时间(0.079 秒)
Evolution of biological therapies in non-small cell lung cancer
biological therapies non-small cell lung cancer
2015/3/26
This article explores recent clinical developments of biological or targeted therapies in non-small cell lung cancer. Molecular research has given us a greater understanding of tumour biology and has ...
Non-small cell lung cancer in the elderly - systemic therapy
Non-small cell lung cancer elderly - systemic therapy
2015/3/26
Elderly patients represent a significant and rising proportion of patients with Non-Small Cell Lung Cancer and historically they have been under-treated and under-represented in clinical trials. Incre...
FDG PET: Revolution or evolution in the management of non-small cell lung cancer?
Revolution evolution management of non-small cell lung cancer
2015/3/11
Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. In Australia there is a falling incidence in males that is not matched in females, t...
Contemporary management of non-small cell lung cancer in Australia
Contemporary management non-small cell lung cancer Australia
2015/3/11
In 1955, Bromley and Szur reported on 66 patients with a pathologic diagnosis of lung cancer who had been treated with high dose radiotherapy and who had then proceeded to surgery1. In 24 (46.7%) no t...
Current status of Radiologic Diagnosis for Mediastinal Lymph Node Metastases of Non-Small-Cell Lung Cancer: Retrospective Study of pN2 Cases
Non-Small-Cell Lung Cancer Mediastinal Lymph Node Metastasis
2013/2/19
Objective: Advances in diagnostic imaging techniques, such as 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), have led to greater accuracy in preoperative mediastinal staging for patien...
A phase I study with Satraplatin and simultaneous chest radiation for non-small cell lung cancer
Non-Small Cell Lung Cancer Chemoradiation Satraplatin Phase I Study Toxicity
2013/1/29
Introduction: Satraplatin has been given in combination therapy for lung cancer to utilize its radio-sensitizing properties. The optimal dose of satra-platin given concurrently with radiation therapy ...
Prognostic Values of PET/CT Findings and Tumor/Patient Characteristics with Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer Survival Prognosis Positron Emission Tomography (PET) FDG-PET
2013/1/31
Background/Aim: Although numerous prognostic factors have been described for non-small cell lung cancer (NSCLC), there is still a requirement for better and non-invasive markers. FDG-PET is a non inva...
Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
Pemetrexed Lung neoplasms Poor performance
2013/12/6
Background and objective Pemetrexed have been approved for the treatment of patients affected by advanced non-small cell lung cancner (NSCLC) in progression after first-line chemotherapy. We evaluated...
The Relationships between cyclin D1 Expression and Prognosis of Non-small Cell Lung Cancer
Lung neoplasms cyclin D1 Prognosis Immunohistochemistry
2013/12/6
Background and objective cyclin D1 is a member of the cyclin family, and it has been proven that it plaied an important role in tumorigenesis, invasion and metastasis. We performed a retrospective stu...
Surgical Therapeutic Strategy for Non-small Cell Lung Cancer with Mediastinal Lymph Node Metastasis (N2)
Lung neoplasms Thoracic surgical procedures Lymphatic metastasis Treatment outcome
2013/12/9
Background and objective Approximately 30% of patients who are diagnosed with non-small cell lung cancer (NSCLC) are classified as N2 on the basis of metastasis to the mediastinal lymph nodes. The eff...
Urginea maritima (L.) Baker (Liliaceae) extract induces more cytotoxicity than standard chemotherapeutics in the A549 non-small cell lung cancer (NSCLC) cell line
Urginea maritima cytotoxicity apoptosis MTT non-small cell lung cancer
2011/3/22
Urginea maritima (Um) is a plant native to especially Turkey and the Mediterranean area. In this study, we investigated whether Um extract exerted cytotoxicity on cancer cells. Materials and methods: ...
Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer
Lung neoplasms Genetic polymorphism Drug therapy
2013/12/10
The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan, oxidized by CYP3A4 to produce inactive compounds, is u...
WEEKLY ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER DURING CHEMOTHERAPY IN A RANDOMIZED PHASE III TRIAL
Adverse event chemotherapy lung cance non-small-cell phase III trial quality of life
2009/7/15
This study investigated quality of life (QOL) in patients with advanced non-small-cell lung cancer in an early phase of chemotherapy in a randomized phase III trial. QOL assessments for four domains (...
Analysis of Cisplatin Behavior in a Non-Small Cell Lung Cancer（NSCLC）Cell Line
cisplatin resistance NSCLC intracellular Pt accumulation Pt-DNA adduct
2009/3/23
Cisplatin (CDDP) is an effective anticancer agent that is widely used in the treatment of testicular, ovarian, bladder and lung cancers. However the development of resistance to CDDP by tumor cells is...
PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
Non small cell lung cancer gemcitabine cisplatin
2010/2/4
Cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (NSCLC). Many novel drugs have been used in combination with cisplatin in this setting. Of these drugs, g...